Cargando…

Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience

BACKGROUND: Precision oncology uses molecular profiling of tumors to identify biomarker‐tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment. This study explored the reasons for attrition on a precision medicin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bohan, Sandy S., Sicklick, Jason K., Kato, Shumei, Okamura, Ryosuke, Miller, Vincent A., Leyland‐Jones, Brian, Lippman, Scott M., Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648352/ https://www.ncbi.nlm.nih.gov/pubmed/32949172 http://dx.doi.org/10.1002/onco.13532

Ejemplares similares

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
por: Gupta, Diviya, et al.
Publicado: (2022)

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
por: Sicklick, Jason K., et al.
Publicado: (2019)

Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
por: Kato, Shumei, et al.
Publicado: (2021)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
por: Sicklick, Jason K., et al.
Publicado: (2021)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
por: Goodman, Aaron M., et al.
Publicado: (2017)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
por: Louie, Bryan H., et al.
Publicado: (2022)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
por: Persha, Hanna E., et al.
Publicado: (2022)

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
por: Miyashita, Hirotaka, et al.
Publicado: (2023)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
por: Kato, Shumei, et al.
Publicado: (2020)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver
por: Deshpande, Anagha, et al.
Publicado: (2022)

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
por: Adashek, Jacob J., et al.
Publicado: (2023)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

MHC-I genotype and tumor mutational burden predict response to immunotherapy
por: Goodman, Aaron M., et al.
Publicado: (2020)

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology
por: Patel, Sandip P., et al.
Publicado: (2015)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden
por: Boichard, Amélie, et al.
Publicado: (2021)

Dermatologic Disease-Directed Targeted Therapy (D(3)T(2)): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology
por: Cohen, Philip R., et al.
Publicado: (2022)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
por: Kato, Shumei, et al.
Publicado: (2018)

Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
por: Saunders, Ila M., et al.
Publicado: (2019)

Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
por: Gupta, Amol, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sc7s9lppasukoh279a0emobot4